Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNK08954 in KRAS G12D mutant advanced solid tumors
NCT06667544Phase 2Recruiting
- Sponsor
- Ranok Therapeutics
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of RNK08954 in solid tumor (advanced stage), sponsored by Ranok Therapeutics. Started Nov 2024; status: recruiting.
02
Drugs
RNK08954
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06667544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667544.